The continued threat of COVID-19 has implications for the long-term management of patients with chronic diseases, including those with IBD.
On Thursday 14th May a panel of leading experts discussed the risks of COVID-19 for people living with IBD, how best to adapt therapy during the current pandemic, and the implications for infusion centres and interventional procedures.
With a live cross to Dr Ryan Ungaro at the Mount Sinai Hospital in New York, we heard how gastroenterologists have navigated the issues surrounding the management of their patients with IBD in this challenging time.
Watch the full recording here:
Listen to the podcasts here:
HOSTED BY
Associate Professor Susan Connor
Head IBD Service, Dept of Gastroenterology, Liverpool Hospital. ANZ IBD Consortium management committee member. Australian IBD Association committee member.
WITH SPECIAL GUESTS
Dr Ryan Ungaro
Assistant Professor of Medicine, Division of Gastroenterology at The Susan and Leonard Feinstein IBD Center and Icahn School of Medicine at Mount Sinai. Co-leader of SECURE-IBD registry.
Dr Britt Christensen
Head of IBD, The Royal Melbourne Hospital (RMH). GESA IBD Faculty, Australian Research Committee, International Bowel Ultrasound Board Member, International Bowel Ultrasound Scientific Committee, IOIBD COVID-19 Task Force (management of outpatient medications)
Dr. John Nik Ding
Gastroenterologist, St Vincent’s Hospital Melbourne. Principal Investigator IBD Clinical Trials. Senior Lecturer Imperial College London and University of Melbourne.
Relevant resources
Principles for Clinicians caring for Patients with IBD during the COVID-19 pandemic
This webinar was developed independently by the limbic. Thank you to AbbVie Pty Ltd for providing the financial support that made it possible.
